The diagnostic value of 124I-PET in patients with differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 5, 2008, Pages 958-965

  Phan, Ha T T ^a   Jager, Pieter L ^b   Paans, Anne M J ^a   Plukker, John T M ^a   Sturkenboom, M G G ^a   Sluiter, W J ^a   Wolffenbuttel, Bruce H R ^a   Dierckx, Rudi A J O ^a   Links, Thera P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Diagnostic value; Differentiated thyroid cancer; Iodine 124; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE; IODINE 124; IODINE 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; THYROID CANCER; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 42149174538     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0660-6     Document Type: Article

References (37)

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
2. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004;11:97-116.
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines Taskforce. Thyroid 2006;16:109-42.
4. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8.
5. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, et al. Follow-up of low-risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-7.
6. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-11.
7. 131I whole body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 2004;14:301-6.
8. Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996;37:1557-62.
9. Lambrecht RM, Woodhouse N, Phillips R, Wolczak D, Qureshi A, Reyes ED, et al. Investigational study of iodine-124 with a positron camera. Am J Physiol Imaging 1988;3:197-200.
10. Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002;29:760-7. DOI 10.1007/s00259-002-0775-8.
11. Crawford DC, Flower MA, Pratt BE, Hill C, Zweit J, McCready VR, et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med 1997;24:1470-8.
12. Flower MA, al-Saadi A, Harmer CL, McCready VR, Ott RJ. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med 1994;21:531-6.
13. Flower MA, Irvine AT, Ott RJ, Kabir F, McCready VR, Harmer CL, et al. Thyroid imaging using positron emission tomography-a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis. Br J Radiol 1990;63:325-30.
14. Ott RJ, Batty V, Webb BS, Flower MA, Leach MO, Clack R, et al. Measurement of radiation dose to the thyroid using positron emission tomography. Br J Radiol 1987;60:245-51.
15. Frey P, Townsend D, Flatted A, De Gautard R, Widgren S, Jeavons A, et al. Tomographic imaging of the human thyroid using 124I. J Clin Endocrinol Metab 1986;63:918-27.
16. Frey P, Townsend D, Jeavons A, Donath A. In vivo imaging of the human thyroid with a positron camera using 124I. Eur J Nucl Med 1985;10:472-6.
17. Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Gorges R, et al. Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004;14:2092-8.
18. Freudenberg LS, Antoch G, Gorges R, Knust J, Pink R, Jentzen W, et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 2003;13 Suppl:L19-23.
19. Georges R, Antoch G, Brandau W, Freudenberg LS, Knust J, Dutschka K, et al. Kombinierte PET/CT mit dem Positronenstrahler 124I bei metastasierten follikularen Schilddrusenkarzinom. Nuklearmedizin 2002;5:N69-71.
20. Lubberink M, van Schie A, de Jong HW, van Dongen GA, Teule GJ. Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I. J Nucl Med 2006;47:1375-81.
21. Van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003;148:589-96.
22. Glaser M, Luthra S, Brady F. Applications of positron-emitting halogens in PET oncology (review). Int J Oncol 2003;22:253-67.
23. Johansson L, Mattsson S, Nosslin B, Leide-Svegborn. Effective dose from radiopharmaceuticals. Eur J Nucl Med 1992;19:933-8 (Erratum in: Eur J Nucl Med 1993;20:570).
24. Berman M, Braverman LE, Burke J, et al. Report No.5 I-123, I-124, I-125, I-126, I-130, I-131, I-132 as sodium iodide. In: Loevinger R, Budinger TF, Watson EE, editors. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine; 1991. p. 49-54.
25. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;8:1366-72.
26. Erdi YE, Macapinlac H, Larson SM, Erdi AK, Yeung H, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging 1999;2:41-6.
27. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910-4.
28. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007;46:121-8.
29. Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2007 (in press); DOI 10.1007/s00259-007-0554-7.
30. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;28:1888-91.
31. 131I. J Nucl Med 2000;41:1198-202.
32. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
33. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Int J Rad Appl Instrum B 1986;13:277-9.
34. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998;39:1546-50.
35. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998;25:242-6.
36. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001;86:3507-11.
37. Waxman A, Ramanna L, Chapman N, Chapman D, Brachman M, Tanasescu D, et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981;22:861-5.